The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,949.00
Bid: 1,952.00
Ask: 1,954.00
Change: -24.00 (-1.22%)
Spread: 2.00 (0.102%)
Open: 1,972.00
High: 1,982.00
Low: 1,949.00
Prev. Close: 1,973.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday preview: WA votes in Parliament, Hikma Pharmaceuticals

Tue, 12th Mar 2019 14:55

(Sharecast News) - Investors may be facing heightened volatility on Wednesday, as financial markets digest the result of Parliament's vote on Theresa May's proposal for the UK's withdrawal agreement with the European Union.Going into the vote, some analysts were putting the odds of a vote in her favour at roughly 10%, which would trigger a vote on a no-deal exit on Wednesday and if the result of that was negative, then a third vote on Thursday on asking Brussels for a short on extension on Article 50.Hence, heightened uncertainty remained, among other reasons because the EU might impose conditions on any extension.As well, there was the possibility of various wildcards to contend with, including May's resignation or a no-confidence vote.Against that backdrop, the Chancellor was to deliver his Spring Statement, although the markets' focus may well turn out to be on the OBR's forecasts for economic growth over the next fiscal year, which might limit Philip Hammond's to dole out largesse.On the corporate side of things, Hikma Pharmaceuticals is among the companies slated to release full-year results.Consensus has penciled-in earnings per share of $1.29 versus $1.05 the last time around on a 6.7% increase in sales to $2.07bn, likely helped by better-than-expected sales of injectables Stateside and higher revenues from its generics arm.But supply disruptions, especially in opioids, meant that management was likely to offer "cautious" guidance on US injectables heading into fiscal year 2019, which might trigger consensus downgrades, Numis analyst Paul Cordon said."We also note the weak recent Q4 performance from Teva and Mylan, which may affect the generics outlook into FY19," he added."We would not expect any further update on the generic Advair program at this point with the trial nearing completion and due to be submitted to the FDA around the middle of the yearWednesday March 13INTERNATIONAL ECONOMIC ANNOUNCEMENTSCrude Oil Inventories (US) (14:30)Industrial Production (EU) (10:00)MBA Mortgage Applications (US) (11:00)Producer Price Index (US) (12:30)Q4Transgloble Energy Corporation NPV (DI)FINALSAdvanced Medical Solutions Group, Avast, Balfour Beatty, Burford Capital , Dignity, ECSC Group, EKF Diagnostics Holdings , Empresaria Group, Gem Diamonds Ltd. (DI), Hikma Pharmaceuticals, Kenmare Resources, Lookers, Manx Telecom , Marshall Motor Holdings, Morrison (Wm) Supermarkets, Prudential, Quilter, SafeCharge International Group Limited (DI), Sigmaroc , Standard Life Aberdeen, StatPro Group, Transgloble Energy Corporation NPV (DI)AGMSIndependent Inv Trust
More News
25 Feb 2021 08:02

UPDATE 2-UK's Hikma misses profit estimate, disappoints on 2021 outlook, share tumbles

* Core operating profit of $566 mln vs consensus of $574 mln* 2021 outlook weaker than analyst expectation* Shares drop nearly 7% (Recasts, adds shares, CEO and analyst comments)By Tanishaa Nadkar and Pushkala AripakaFeb 25 (Reuters) - Hikma Pharmac...

Read more
25 Feb 2021 08:01

LONDON MARKET PRE-OPEN: ABF's Primark Loses GBP1.1 Billion In Sales

LONDON MARKET PRE-OPEN: ABF's Primark Loses GBP1.1 Billion In Sales

Read more
18 Feb 2021 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
15 Feb 2021 09:40

BROKER RATINGS: Bernstein Lifts Reckitt; Liberum Cuts Moneysupermarket

BROKER RATINGS: Bernstein Lifts Reckitt; Liberum Cuts Moneysupermarket

Read more
3 Feb 2021 09:17

UPDATE 2-Healthcare drags FTSE 100 down; Vodafone jumps

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* GlaxoSmithKline slumps on COVID-19 vaccine development* Vodafone gains after earnings beat estimates* Glencore rises after maintaining 2021...

Read more
1 Feb 2021 13:44

Monday broker round-up

(Sharecast News) - Polymetal International: Berenberg reiterates buy with a target price of 2,310p.

Read more
26 Jan 2021 08:28

TOP NEWS: Hikma In Talks To Buy Glaxo Businesses In Egypt And Tunisia

TOP NEWS: Hikma In Talks To Buy Glaxo Businesses In Egypt And Tunisia

Read more
12 Jan 2021 10:13

Vectura Forecasts 2020 Earnings To Top Board Expectations

Vectura Forecasts 2020 Earnings To Top Board Expectations

Read more
18 Dec 2020 17:08

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
2 Dec 2020 13:11

Wednesday broker round-up

(Sharecast News) - Royal Dutch Shell A: JP Morgan upgrades to overweight with a target price of 1,700p.

Read more
24 Nov 2020 13:33

Tuesday broker round-up

(Sharecast News) - Glencore: Jefferies upgrades to buy with a target price of 250p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.